Itamar Medical Ltd. (NASDAQ:ITMR) has been given a consensus recommendation of “Hold” by the seven brokerages that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $31.17.
A number of equities research analysts have recently issued reports on ITMR shares. Zacks Investment Research raised shares of Itamar Medical from a “sell” rating to a “hold” rating in a report on Tuesday, August 10th. SVB Leerink dropped their target price on shares of Itamar Medical from $33.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, May 20th. Alliance Global Partners cut shares of Itamar Medical from a “buy” rating to a “neutral” rating in a report on Tuesday. LADENBURG THALM/SH SH cut shares of Itamar Medical from a “buy” rating to a “neutral” rating and set a $33.85 target price on the stock. in a report on Wednesday. Finally, HC Wainwright cut shares of Itamar Medical from a “buy” rating to a “neutral” rating and dropped their target price for the company from $36.00 to $31.00 in a report on Tuesday.
Several large investors have recently made changes to their positions in the business. M&T Bank Corp bought a new stake in shares of Itamar Medical during the 1st quarter worth approximately $235,000. Phoenix Holdings Ltd. lifted its holdings in shares of Itamar Medical by 192.4% during the 1st quarter. Phoenix Holdings Ltd. now owns 153,088 shares of the company’s stock worth $3,651,000 after acquiring an additional 100,724 shares during the period. Principal Financial Group Inc. bought a new stake in shares of Itamar Medical during the 1st quarter worth approximately $633,000. Russell Investments Group Ltd. lifted its holdings in shares of Itamar Medical by 10.5% during the 1st quarter. Russell Investments Group Ltd. now owns 117,725 shares of the company’s stock worth $2,818,000 after acquiring an additional 11,146 shares during the period. Finally, UBS Group AG lifted its holdings in shares of Itamar Medical by 28.7% during the 1st quarter. UBS Group AG now owns 3,211 shares of the company’s stock worth $77,000 after acquiring an additional 716 shares during the period. Hedge funds and other institutional investors own 43.52% of the company’s stock.
Itamar Medical (NASDAQ:ITMR) last released its earnings results on Tuesday, August 31st. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). Equities analysts anticipate that Itamar Medical will post -1.25 earnings per share for the current fiscal year.
About Itamar Medical
Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease.
Featured Story: What sectors are represented in the Nikkei Index?
Receive News & Ratings for Itamar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Itamar Medical and related companies with MarketBeat.com's FREE daily email newsletter.